NCT00725270

Treatment of Schizoaffective Disorder Using Mifepristone

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.

Detailed description

You are invited to participate in a research study which evaluates the effectiveness of mifepristone (RU 486) in rapidly reducing the symptoms associated with schizoaffective disorder. Our group believes that the cognitive deficits (a decline in the ability to think clearly) and psychosis (hallucinations or delusions) exhibited in some affective disorders are driven by an excess of stress hormone effects (hypercortisolemia). Often the origin of this hormonal imbalance is unknown. Current treatment for schizoaffective disorder (characterized by mood swings and hallucinations and/or delusions) involves using a combination of antidepressant medication (for mood elevation), mood stabilizing medications (to prevent extreme high and low moods) and antipsychotic medication (for the correction of altered thinking). While these therapies are often effective, they can take several weeks or longer to work. We hope to uncover a quick, effective, safe therapy for the treatment of individuals with your condition.

Conditions

• Psychotic Disorders
• Depressive Disorder, Major
• Depressive Disorder

Interventions

Type	Name	Description
DRUG	Mifepristone	600 mg of mifepristone
DRUG	Placebo Oral Tablet	Placebo comparator

Timeline

• Start date: 1998-04-01
• Primary completion: 2009-05-01
• Completion: 2009-05-01
• First posted: 2008-07-30
• Last updated: 2017-03-24
• Results posted: 2017-03-24

Locations

1 site across 1 country: United States